Arcturus Therapeutics Holdings Inc. (ARCT)
| Market Cap | 431.75M -8.0% |
| Revenue (ttm) | 29.37M -76.0% |
| Net Income | -93.28M |
| EPS | -3.33 |
| Shares Out | 28.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,619,519 |
| Open | 15.43 |
| Previous Close | 16.17 |
| Day's Range | 14.49 - 15.90 |
| 52-Week Range | 5.50 - 24.17 |
| Beta | 2.27 |
| Analysts | Buy |
| Price Target | 20.20 (+32.98%) |
| Earnings Date | Aug 6, 2026 |
About ARCT
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi... [Read more]
Financial Performance
In 2025, ARCT's revenue was $82.03 million, a decrease of -46.14% compared to the previous year's $152.31 million. Losses were -$65.78 million, -18.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price target is $20.2, which is an increase of 32.98% from the latest price.
News
Arcturus Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is advancing two flagship mRNA programs for cystic fibrosis and OTC deficiency, both nearing phase III with significant unmet needs and commercial potential. A unique Thermo Fisher partnership supports CF development, while strong cash reserves and regained vaccine rights provide strategic flexibility.
Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord
Canaccord lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $20 from $21 and keeps a Buy rating on the shares. The firm said in its 2Q26 report that…
Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2026
Phase II studies for ARCT-032 and ARCT-810 advanced, with ARCT-810 completing enrollment and dosing. Regained global rights to the KOSTAIVE vaccine and broader saRNA platform, strengthening strategic control. Cash runway extends through 2028, supporting key milestones.
Arcturus Therapeutics Holdings Earnings release: Q2 2026
Arcturus Therapeutics Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Arcturus Therapeutics Holdings Quarterly report: Q2 2026
Arcturus Therapeutics Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
Roth Capital analyst Adam Walsh keeps a Buy rating and $20 price target on shares of Arcturus Therapeutics (ARCT). The Thermo Fisher (TMO) collaboration on ARCT-032 Phase 3 is viewed…
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
Arcturus Therapeutics (ARCT) announced a strategic collaboration with Thermo Fisher Scientific (TMO) to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ inve...
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rar...
Arcturus Therapeutics initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $27 price target Arcturus is a clinical-stage mRNA medicines company focused on rare liver and respiratory disea...
Arcturus could halve the grid's electrical losses using its nano-infused copper
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all ...
Arcturus Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted advances in mRNA therapeutics, with clinical progress in cystic fibrosis and OTC deficiency programs, and a differentiated, scalable delivery platform. The COVID vaccine is approved in 32 countries, and new board members bring deep industry expertise.
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference.
Arcturus Therapeutics Holdings Transcript: 16th Annual LD Micro Invitational Conference
The company is advancing next-generation mRNA medicines with unique delivery technologies, focusing on inhaled therapeutics for cystic fibrosis and rare liver diseases, both in phase II trials. Their self-amplifying mRNA vaccine platform has shown superior efficacy and durability, with strong government and foundation partnerships.
Arcturus Therapeutics Holdings Earnings Call Transcript: Q1 2026
Advanced CF and OTC programs with a 12-week phase II CF study underway and clear FDA guidance for pediatric OTC. Revenue and expenses declined year-over-year as focus shifted to rare diseases, maintaining a cash runway beyond Q2 2028.
Arcturus Therapeutics Holdings Earnings release: Q1 2026
Arcturus Therapeutics Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Arcturus Therapeutics Holdings Quarterly report: Q1 2026
Arcturus Therapeutics Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of live...
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of live...
Arcturus Therapeutics Holdings Proxy statement: Proxy filing
Arcturus Therapeutics Holdings filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Arcturus Therapeutics Holdings Transcript: The 38th Annual Roth Conference
The company is refocusing on rare diseases with its mRNA platform, advancing ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis. Regulatory clarity for pediatric trials is expected in Q2 2024, and the cash runway extends into Q2 2028, with additional funding likely needed for late-stage trials.
Arcturus Therapeutics initiated with a Buy at B. Riley
B. Riley initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $22 price target The firm says the company “stands out” given its lipid-enabled and unlocked nucleic acid…
Arcturus Therapeutics Holdings Transcript: Leerink Global Healthcare Conference 2026
Recent progress includes well-tolerated phase II CF dosing, early efficacy signals, and a 12-week study with expanded endpoints and sites. The OTC program is prioritizing pediatric development, pending FDA guidance. KOSTAIVE vaccine approvals continue, with financial runway into Q2 2028, excluding arbitration outcomes.